Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine + Low-dose Dasatinib in AML Maintenance
NCT05042531Phase 2Unknown
- Sponsor
- Lanzhou University
- Start
- Nov 2021
- Primary completion
- Sep 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in acute myeloid leukemia (AML), sponsored by Lanzhou University. Status: unknown.
02
Drugs
dasatinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05042531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05042531.